news ILC2s sensitise pancreatic tumours to PD-1 checkpoint inhibitors in mice 25 February 2020 | By Hannah Balfour (Drug Target Review) Scientists identify innate lymphoid cells (ILCs) as possible targets for immunotherapies as their activation makes murine pancreatic tumours sensitive to PD-1 checkpoint inhibitors.